Polyclonal Antibody to Eosinophil Chemotactic Factor (ECF)
| Code | Size | Price |
|---|
| PAA025Hu02-20ul | 20ul | £88.00 |
Quantity:
| PAA025Hu02-100ul | 100ul | £165.00 |
Quantity:
| PAA025Hu02-200ul | 200ul | £223.00 |
Quantity:
| PAA025Hu02-1ml | 1ml | £512.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CCL11; SCYA11; Eotaxin 1; Eosinophil Chemotactic Protein 1; Chemokine C-C-Motif Ligand 11; Small Inducible Cytokine Subfamily A(Cys-Cys)Member 11
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Immunogen:
RPA025Hu02-Recombinant Eosinophil Chemotactic Factor (ECF)
Item Name:
Eosinophil Chemotactic Factor
Source:
Polyclonal antibody preparation
Subcategory:
Polyclonal antibody preparation
USAGE:
Western blotting: 0.5-2ug/mL
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Eosinophil Chemotactic Factor (ECF) | RPA025Hu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||